Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | FAAH | O00519 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | KLF5 | Q13887 | 2/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4498512 | 0.88 | CPB2 (0.54) | LMNAFAAHCPB2 | |
| SCHEMBL4500182 | 0.85 | CPB2 (0.47) | RAB9ANPC1CPB2NAMPTSLC7A5 | |
| SCHEMBL4515230 | 0.81 | CPB2 (0.57) | CPB2 | |
| SCHEMBL4493363 | 0.79 | CPB2 (0.55) | CPB2 | |
| SCHEMBL4496593 | 0.79 | CPB2 (0.48) | CPB2SLC7A5 | |
| SCHEMBL6474709 | 0.78 | CPB2 (0.52) | RAB9ANPC1LMNAKMT2AMEN1 | |
| SCHEMBL4505145 | 0.77 | CPB2 (0.49) | PARP1KMT2ACPB2 | |
| SCHEMBL4506255 | 0.76 | CPB2 (0.54) | FAAHCPB2 | |
| SCHEMBL4508198 | 0.76 | CPB2 (0.48) | RAB9ANPC1LMNAKMT2AMEN1 | |
| SCHEMBL4521167 | 0.76 | CPB2 (0.57) | CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572817-B2 | 2,5-disubstituted 3-mercaptopentanoic acid | ASTRAZENECA AB (SE) | 2009-08-11 | — | — | US | claimed |
| US-7572817-B2 | 2,5-disubstituted 3-mercaptopentanoic acid | ASTRAZENECA AB (SE) | 2009-08-11 | — | — | US | disclosed |
| EP-1532111-B1 | 2,5-DISUBSTITUTED 3-MERCAPTOPENTANOIC ACID | ASTRAZENECA AB (SE) | 2007-08-08 | — | — | EP | disclosed |
| US-20050176780-A1 | 2,5-disubstituted 3-mercaptopentanoic acid | ASTRAZENECA AB (SE) | 2005-08-11 | — | — | US | disclosed |
| EP-1532111-A1 | 2,5-DISUBSTITUTED 3-MERCAPTOPENTANOIC ACID | AstraZeneca AB (SE) | 2005-05-25 | — | — | EP | disclosed |
| WO-2003106420-A1 | 2,5-DISUBSTITUTED 3-MERCAPTOPENTANOIC ACID | ASTRAZENECA AB (SE) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176780-A1 | 2,5-disubstituted 3-mercaptopentanoic acid | METAP1, MPST, DNPEP | RAB9A 4389/4885NPC1 984/4885PARP1 3254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.